• Explore /
  • Poster
  • / Obinutuzumab (G)-atezolizumab (atezo)-lenalidomide (len) for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL): Final analysis of a phase Ib/II trial.

Obinutuzumab (G)-atezolizumab (atezo)-lenalidomide (len) for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL): Final analysis of a phase Ib/II trial.

Abstract Video & Slides Poster

Authors

Nilanjan Ghosh

Nilanjan Ghosh

Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC

Nilanjan Ghosh , Gilles A. Salles , Izidore S. Lossos , Maria Lia Palomba , Amitkumar Mehta , Olivier Casasnovas , Don A. Stevens , Sudhakar Katakam , Andrea Knapp , Tina Nielsen , Franck Morschhauser

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT02631577

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 7511)

DOI

10.1200/JCO.2021.39.15_suppl.7511

Abstract #

7511

Abstract Disclosures

Similar Posters

First Author: Ian W. Flinn

First Author: Christopher Flowers

First Author: Pier Luigi Zinzani

First Author: Lorenzo Falchi